Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX

BACKGROUND/AIMS: There has been growing evidence on the utility of neoadjuvant FOLFIRINOX in borderline resectable (BR) or locally advanced (LA) pancreatic cancer. However, factors predicting survival in these patients remain to be identified, and we aimed to identify these prognostic factors. METHO...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Gut Liver
Auteurs principaux: Choi, Young Hoon, Lee, Sang Hyub, You, Min Su, Shin, Bang Sup, Paik, Woo Hyun, Ryu, Ji Kon, Kim, Yong-Tae, Kwon, Wooil, Jang, Jin-Young, Kim, Sun-Whe
Format: Artigo
Langue:Inglês
Publié: Editorial Office of Gut and Liver 2021
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7960979/
https://ncbi.nlm.nih.gov/pubmed/32235008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5009/gnl19182
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires